Technical Analysis for COGT - Cogent Biosciences, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Spinning Top | Other | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 5.03% | |
| Inside Day | Range Contraction | 5.03% | |
| Wide Bands | Range Expansion | 5.03% | |
| Gapped Up | Strength | 5.03% | |
| Slingshot Bullish | Bullish Swing Setup | 5.03% | |
| Upper Bollinger Band Walk | Strength | 5.03% | |
| Wide Bands | Range Expansion | 5.03% |
| Alert | Time |
|---|---|
| Non-ADX 1,2,3,4 Pullback Entry | about 18 hours ago |
| Rose Above Previous Day's High | about 18 hours ago |
| Up 5% | about 18 hours ago |
| Up 1 ATR | about 18 hours ago |
| Gap Up Partially Closed | about 18 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/07/2024
Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies for genetically defined diseases. Cogent's most advanced program, PLX9486, is a highly selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving a rare and serious condition called Systemic Mastocytosis, and exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. Cogent is headquartered in Cambridge, MA.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Clinical Medicine Disease Gastrointestinal Enzymes Protein Kinase Inhibitor Tyrosine Kinase Mastocytosis Systemic Mastocytosis Gastrointestinal Stromal Tumor Imatinib Gastrointestinal Stromal Tumors
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Clinical Medicine Disease Gastrointestinal Enzymes Protein Kinase Inhibitor Tyrosine Kinase Mastocytosis Systemic Mastocytosis Gastrointestinal Stromal Tumor Imatinib Gastrointestinal Stromal Tumors
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 13.5 |
| 52 Week Low | 3.67 |
| Average Volume | 1,434,066 |
| 200-Day Moving Average | 7.94 |
| 50-Day Moving Average | 6.80 |
| 20-Day Moving Average | 7.09 |
| 10-Day Moving Average | 7.57 |
| Average True Range | 0.51 |
| RSI (14) | 59.68 |
| ADX | 20.67 |
| +DI | 21.62 |
| -DI | 13.96 |
| Chandelier Exit (Long, 3 ATRs) | 6.55 |
| Chandelier Exit (Short, 3 ATRs) | 7.40 |
| Upper Bollinger Bands | 8.20 |
| Lower Bollinger Band | 5.98 |
| Percent B (%b) | 0.79 |
| BandWidth | 31.27 |
| MACD Line | 0.26 |
| MACD Signal Line | 0.21 |
| MACD Histogram | 0.0493 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 8.47 | ||||
| Resistance 3 (R3) | 8.44 | 8.15 | 8.35 | ||
| Resistance 2 (R2) | 8.15 | 7.96 | 8.17 | 8.30 | |
| Resistance 1 (R1) | 7.94 | 7.84 | 8.05 | 7.97 | 8.26 |
| Pivot Point | 7.65 | 7.65 | 7.71 | 7.67 | 7.65 |
| Support 1 (S1) | 7.44 | 7.46 | 7.55 | 7.47 | 7.18 |
| Support 2 (S2) | 7.15 | 7.34 | 7.17 | 7.14 | |
| Support 3 (S3) | 6.94 | 7.15 | 7.10 | ||
| Support 4 (S4) | 6.97 |
